Post-operative seroma formation remains one of the most common complications following breast cancer surgery. This prospective randomized controlled trial was conducted to evaluate the efficacy of Micronized Purified Flavonoid Fraction (Daflon) in reducing post-operative seroma formation in patients undergoing breast cancer surgery with sentinel lymph node biopsy or axillary lymph node dissection.

This single-center prospective randomized controlled study was conducted at the Breast Surgery Unit, Ittefaq Hospital Trust, Lahore. Female patients undergoing breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary lymph node dissection for breast cancer were included. Participants were randomized into intervention and control groups according to surgical procedure strata. The intervention arm received Daflon 500 mg twice daily for four weeks post-operatively. Outcomes included seroma formation, drain output, and drain removal duration.

Inclusion Criteria:

- Patients undergoing breast cancer surgery, including either breast-conserving surgery or mastectomy with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND), during the study period were included

Exclusion Criteria:

• Patients were excluded if they had pre-existing disease-related upper limb lymphedema, had undergone extensive oncoplastic procedures such as latissimus dorsi myocutaneaous flap (LDMF) or deep inferior epigastric perforator (DIEP) flap reconstruction, had a previously irradiated breast, or underwent only wide local excision under local anaesthesia in the setting of American Society of Anaesthesiologists (ASA) class IV or higher.

Individual participant data will not be publicly shared due to institutional data protection policies and participant confidentiality considerations